Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

키워드

참고문헌 (137)

1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Molina JR, "Non-small cell lung cancer : epidemiology, risk factors, treatment, and survivorship", Mayo Clin Proc, 83, pp.584~594 (2008)
3. Scagliotti GV, "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer", J Clin Oncol, 26, pp.3543~3551 (2008)
4. Paz-Ares LG, "PARAMOUNT : Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer", J Clin Oncol, 31, pp.2895~2902 (2013)
5. Patel JD, "PointBreak : a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer", J Clin Oncol, 31, pp.4349~4357 (2013)
6. Wu YL, "Phase III, randomized, open-label, first-line study in Asia of gefi-tinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer : evaluation of patients recruited from mainland China, 2012, pp.8, 232~243
7. Sudhesh Dev S, "Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer", Front Pharmacol, 12, pp.772510~ (2021)
8. Lugowska I, "Trametinib : a MEK inhibitor for management of metastatic melanoma", Onco Targets Ther, 8, pp.2251~2259 (2015)
9. Skoulidis F, "Sotorasib for lung cancers with KRAS p.G12C mutation", N Engl J Med, 384, pp.2371~2381 (2021)
10. Drago JZ, "Unlocking the potential of antibody-drug conjugates for cancer therapy", Nat Rev Clin Oncol, 18, pp.327~344 (2021)
11. Li BT, "Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer", N Engl J Med, 386, pp.241~251 (2022)
12. Peters S, "Trastuzumab emtansine(T-DM1)in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer : efficacy, safety, and biomarkers", Clin Cancer Res, 25, pp.64~72 (2019)
13. Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
14. Sequist LV, "First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations", J Clin Oncol, 26, pp.2442~2449 (2008)
15. Wu YL, "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050) : a randomised, open-label, phase 3 trial", Lancet Oncol, 18, pp.1454~1466 (2017)
16. Park K, "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUX-Lung 7) : a phase 2B, open-label, randomised controlled trial", Lancet Oncol, 17, pp.577~589 (2016)
17. Ramalingam SS, "Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC", N Engl J Med, 382, pp.41~50 (2020)
18. Peters S, "Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer", N Engl J Med, 377, pp.829~838 (2017)
19. Solomon BJ, "First-line crizotinib versus chemotherapy in ALK-positive lung cancer", N Engl J Med, 371, pp.2167~2177 (2014)
20. Soria JC, "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer(ASCEND-4) : a randomised, open-label, phase 3 study", Lancet, 389, pp.917~929 (2017)
21. Camidge DR, "Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer : second interim analysis of the phase III ALTA-1L trial", J Clin Oncol, 38, pp.3592~3603 (2020)
22. Shaw AT, "First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer", N Engl J Med, 383, pp.2018~2029 (2020)
23. Shaw AT, "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer(NSCLC) : updated results, including overall survival, from PROFILE 1001", Ann Oncol, 30, pp.1121~1126 (2019)
24. Lim SM, "Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1rearrangement", J Clin Oncol, 35, pp.2613~2618 (2017)
25. Dziadziuszko R, "Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer", J Clin Oncol, 39, pp.1253~1263 (2021)
26. Planchard D, "Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC : updated 5-year survival rates and genomic analysis", J Thorac Oncol, 17, pp.103~115 (2022)
27. Hong DS, "Larotrectinib in patients with TRK fusion-positive solid tumours : a pooled analysis of three phase 1", 2 clinical trials, 2020, pp.21, 531~540
28. Doebele RC, "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : integrated analysis of three phase 1-2 trials", Lancet Oncol, 21, pp.271~282 (2020)
29. Drilon A, "Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer", N Engl J Med, 383, pp.813~824 (2020)
30. Gainor JF, "Pralsetinib for RET fusion-positive non-small-cell lung cancer(ARROW) : a multi-cohort, open-label, phase 1", 2 study, 2021, pp.22, 959~969
31. Wolf J, "Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer", N Engl J Med, 383, pp.944~957 (2020)
32. Paik PK, "Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations", N Engl J Med, 383, pp.931~943 (2020)
33. Hong DS, "KRAS(G12C)inhibition with sotorasib in advanced solid tumors", N Engl J Med, 383, pp.1207~1217 (2020)
34. Park K, "Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy : initial results from the CHRYSALIS phase I study", J Clin Oncol, 39, pp.3391~3402 (2021)
35. Zhou C, "Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer : a phase 1", 2 open-label nonrandomized clinical trial, 2021, pp.7, e214761~
36. Wu YL, "Osimertinib in resected EGFR-mutated non-small-cell lung cancer", N Engl J Med, 383, pp.1711~1723 (2020)
37. Mielgo-Rubio X, "Targeted therapy moves to earlier stages of non-small-cell lung cancer : emerging evidence, controversies and future challenges", Future Oncol, 17, pp.4011~4025 (2021)
38. Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
39. Dagogo-Jack I, "Tumour heterogeneity and resistance to cancer therapies", Nat Rev Clin Oncol, 15, pp.81~94 (2018)
40. Aldea M, "Overcoming resistance to tumor-targeted and immune-targeted therapies", Cancer Discov, 11, pp.874~899 (2021)
41. Jamal-Hanjani M, "Tracking the evolution of non-small-cell lung cancer", N Engl J Med, 376, pp.2109~2121 (2017)
42. Gerlinger M, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing", N Engl J Med, 366, pp.883~892 (2012)
43. Michor F, "The origins and implications of intratumor heterogeneity", Cancer Prev Res(Phila), 3, pp.1361~1364 (2010)
44. Lovly CM, "Tumor heterogeneity and therapeutic resistance", Am Soc Clin Oncol Educ Book, 35, pp.e585~e593 (2016)
45. Piotrowska Z, "Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor", Cancer Discov, 5, pp.713~722 (2015)
46. Jackman D, "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer", J Clin Oncol, 28, pp.357~360 (2010)
47. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
48. Niederst MJ, "The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies", Clin Cancer Res, 21, pp.3924~3933 (2015)
49. Arulananda S, "Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer", J Thorac Oncol, 12, pp.1728~1732 (2017)
50. Jia Y, "Overcoming EGFR(T790M)and EGFR(C797S)resistance with mutant-selective allosteric inhibitors", Nature, 534, pp.129~132 (2016)
51. Wang S, "EAI045 : the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance", Cancer Lett, 385, pp.51~54 (2017)
52. Schalm SS, "1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M", C797S resistant NSCLC, 2020, pp.31(Suppl 4), S839~
53. Shaw AT, "ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer", J Clin Oncol, 37, pp.1370~1379 (2019)
54. Zhang S, "The potent ALK inhibitor brigatinib(AP26113)overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models", Clin Cancer Res, 22, pp.5527~5538 (2016)
55. Kim DW, "Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer : a randomized, multicenter phase II trial", J Clin Oncol, 35, pp.2490~2498 (2017)
56. Pan Y, "The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer", Front Oncol, 11, pp.713530~ (2021)
57. Drilon A, "Repotrectinib(TPX-0005)is a next-generation ROS1", TRK, TRK, pp.ALK solvent-front mutations, Cancer Discov[DOI]
58. Neel DS, "Resistance is futile : overcoming resistance to targeted therapies in lung adenocarcinoma", NPJ Precis Oncol, 1, pp.3~ (2017)
59. Mikubo M, "Mechanism of drug tolerant persister cancer cells : the landscape and clinical implication for therapy", J Thorac Oncol, 16, pp.1798~1809 (2021)
60. Leonetti A, "Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer", Br J Cancer, 121, pp.725~737 (2019)
61. Marine JC, "Non-genetic mechanisms of therapeutic resistance in cancer", Nat Rev Cancer, 20, pp.743~756 (2020)
62. Albertson DG, "Gene amplification in cancer", Trends Genet, 22, pp.447~455 (2006)
63. Holland AJ, "Chromoanagenesis and cancer : mechanisms and consequences of localized, complex chromosomal rearrangements", Nat Med, 18, pp.1630~1638 (2012)
64. Ungefroren H, "Autocrine TGF-beta in cancer : review of the literature and caveats in experimental analysis", Int J Mol Sci, 22, pp.977~ (2021)
65. Tulpule A, "Acquired resistance in lung cancer", Annu Rev Cancer Biol, 4, pp.279~297 (2020)
66. Mazieres J, "Vemurafenib in non-small-cell lung cancer patients with BRAF(V600)and BRAF(nonV600)mutations", Ann Oncol, 31, pp.289~294 (2020)
67. Liu Q, "EGFR-TKIs resistance via EGFR-independent signaling pathways", Mol Cancer, 17, pp.53~ (2018)
68. Yuan M, "The emerging treatment landscape of targeted therapy in non-small-cell lung cancer", Signal Transduct Target Ther, 4, pp.61~ (2019)
69. Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
70. Zhang GC, "Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients", Clin Oncol(R Coll Radiol), 19, pp.499~506 (2007)
71. Zhang G, "Function of Axl receptor tyrosine kinase in non-small cell lung cancer", Oncol Lett, 15, pp.2726~2734 (2018)
72. Taniguchi H, "AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells", Nat Commun, 10, pp.259~ (2019)
73. Sarantopoulos J, "A phase Ia", b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours, 2019, pp.30(Suppl 5), V172~
74. Yu HA, "Concurrent alterations in EGFR-Mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance", Clin Cancer Res, 24, pp.3108~3118 (2018)
75. Roeper J, "TP53 co-mutations in EGFR mutated patients in NSCLC stage IV : A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC", Oncotarget, 11, pp.250~264 (2020)
76. Canale M, "Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors", Clin Cancer Res, 23, pp.2195~2202 (2017)
77. Wang WX, "TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib", J Thorac Dis, 10, pp.2991~2998 (2018)
78. Kron A, "Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer", Ann Oncol, 29, pp.2068~2075 (2018)
79. Gen L, "Concurrent TP53 mutation adversely impact the efficacy of crizotinib in ROS1-rearranged lung cancer patients", J Clin Oncol, 37(15_Suppl), pp.e20535~ (2019)
80. Alidousty C, "Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC : a central role of TP53 mutations", J Pathol, 246, pp.67~76 (2018)
81. Quintanal-Villalonga A, "Lineage plasticity in cancer : a shared pathway of therapeutic resistance", Nat Rev Clin Oncol, 17, pp.360~371 (2020)
82. Zellmer VR, "Evolving concepts of tumor heterogeneity", Cell Biosci, 4, pp.69~ (2014)
83. Lee JK, "Clonal history and genetic predictors of transformation Into small-cell carcinomas from lung adenocarcinomas", J Clin Oncol, 35, pp.3065~3074 (2017)
84. Takegawa N, "Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in asso-ciation with acquired resistance to alectinib", Ann Oncol, 27, pp.953~955 (2016)
85. Fujita S, "Transformation to SCLC after treatment with the ALK inhibitor alectinib", J Thorac Oncol, 11, pp.e67~e72 (2016)
86. Hobeika C, "ALK-rearranged adenocarcinoma transformed to small-cell lung cancer : a new entity with specific prognosis and treatment?", Per Med, 15, pp.111~115 (2018)
87. Zhang Y, "Case report : a case report of a histological transformation of ALK-rearranged adenocarcinoma with high expression of PD-L1 to squamous cell carcinoma after treatment with alectinib", Pathol Oncol Res, 27, pp.637745~ (2021)
88. Awad MM, "Acquired resistance to KRAS(G12C)inhibition in cancer", N Engl J Med, 384, pp.2382~2393 (2021)
89. Niederst MJ, "RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer", Nat Commun, 6, pp.6377~ (2015)
90. Quintanal-Villalonga A, "Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation", Cancer Discov, 11, pp.3028~3047 (2021)
91. Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 3, pp.75~ (2011)[DOI]
92. Sung WJ, "The biological role of epithelial-mesenchymal transition in lung cancer(Review)", Oncol Rep, 36, pp.1199~1206 (2016)
93. Weng CH, "Epithelial-mesenchymal transition(EMT)beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI", Oncogene, 38, pp.455~468 (2019)
94. Zhu X, "EMT-mediated acquired EGFR-TKI resistance in NSCLC : mechanisms and strategies", Front Oncol, 9, pp.1044~ (2019)
95. Zhu C, "AXL receptor tyrosine kinase as a promising anti-cancer approach : functions, molecular mechanisms and clinical applications", Mol Cancer, 18, pp.153~ (2019)
96. Oren Y, "Cycling cancer persister cells arise from lineages with distinct programs", Nature, 596, pp.576~582 (2021)
97. Sharma SV, "A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations", Cell, 141, pp.69~80 (2010)
98. Cabanos HF, "Emerging insights into targeted therapy-tolerant persister cells in cancer", Cancers(Basel), 13, pp.2666~ (2021)
99. Zakaria N, "Targeting lung cancer stem cells : research and clinical impacts", Front Oncol, 7, pp.80~ (2017)
100. Gomez DR, "Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy : a multicentre, randomised, controlled, phase 2 study", Lancet Oncol, 17, pp.1672~1682 (2016)
101. Khan KH, "Hyperglycemia and phosphatidylinositol 3-kinase", protein kinase B, AKT, pp.mTOR)inhibitors in phase I trials : incidence, predictive factors, and management, Oncologist[DOI]
102. Robinson ES, "Hypertension induced by vascular endothelial growth factor signaling pathway inhibition : mechanisms and potential use as a biomarker", Semin Nephrol, 30, pp.591~601 (2010)
103. Perez-Soler R, "Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer", Clin Lung Cancer, 8(Suppl 1), pp.S7~S14 (2006)
104. Chu CY, "Osimertinib : a novel dermatologic adverse event profile in patients with lung cancer", Oncologist, 23, pp.891~899 (2018)
105. Kunimasa K, "Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib", JACC CardioOncol, 2, pp.1~10 (2020)
106. Van Leeuwen MT, "Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews", JNCI Cancer Spectr, 4, pp.pkaa076~ (2020)
107. Uprety D, "Targeting the cardiotoxicity of epidermal growth factor receptor inhibitors", JACC CardioOncol, 2, pp.11~12 (2020)
108. Chen T, "Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients", J Thorac Dis, 11, pp.2251~2266 (2019)
109. Wheatley-Price P, "Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21", J Clin Oncol, 26, pp.2350~2357 (2008)
110. Corre R, "Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor : a multicentric real-world study assessing tolerance and efficacy(OCTOMUT study)", Oncotarget, 9, pp.8253~8262 (2018)
111. Drilon A, "Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children", N Engl J Med, 378, pp.731~739 (2018)
112. Drilon A, "Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers", JCO Precis Oncol, 6, pp.e2100418~ (2022)
113. Solomon BJ, "Lorlatinib in patients with ALK-positive non-small-cell lung cancer : results from a global phase 2 study", Lancet Oncol, 19, pp.1654~1667 (2018)
114. Kelly WJ, "Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer", Front Oncol, 8, pp.208~ (2018)
115. Reungwetwattana T, "CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer", J Clin Oncol, 36, pp.JCO2018783~ (2018)
116. Griesinger F, "Brain metastases in ALK-positive NSCLC : time to adjust current treatment algorithms", Oncotarget, 9, pp.35181~35194 (2018)
117. Goldie JH, "A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate", Cancer Treat Rep, 63, pp.1727~1733 (1979)
118. DeVita VT, "Devita, Hellman and Rosenberg’s cancer: principles and practice of oncology", pp.2011, Wolters Kluwer Health
119. Weickhardt A, "A phase I", II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12(cixutumumab)in patients with advanced non-small cell lung cancer, 2012, pp.7, 419~426
120. Hamilton M, "Effects of smoking on the pharmacokinetics of erlotinib", Clin Cancer Res, 12, pp.2166~2171 (2006)
121. Solassol I, "FDA-and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer : safety, tolerability, plasma concentration monitoring, and management", Biomolecules, 9, pp.668~ (2019)
122. Peters S, "Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer : comparative pharmacokinetics and drug-drug interactions", Cancer Treat Rev, 40, pp.917~926 (2014)
123. Zhao D, "Pharmacokinetic-based drug-drug interactions with anaplastic lymphoma kinase inhibitors : a review", Drug Des Devel Ther, 14, pp.1663~1681 (2020)
124. Suttle AB, "Assessment of the drug interaction potential and single-and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib", J Clin Pharmacol, 55, pp.392~400 (2015)
125. Willemsen AE, "Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors", Drug Discov Today, 21, pp.962~976 (2016)
126. Singh BN, "Effects of food on the clinical pharmacokinetics of anticancer agents : underlying mechanisms and implications for oral chemotherapy", Clin Pharmacokinet, 43, pp.1127~1156 (2004)
127. Wu CY, "Predicting drug disposition via application of BCS : transport", absorption, Pharm Res, pp.2005, 22[DOI]
128. Chu E, "Physicians’ cancer chemotherapy: drug manual 2021" (2021), Jones & Bartlett Learning
129. Ling J, "Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals", Anticancer Drugs, 19, pp.209~216 (2008)
130. Ruwali M, "Updates in pharmacogentetics of non-small cell lung cancer" (2021), IntechOpen
131. Nomura M, "Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers", PLoS Med, 4, pp.e125~ (2007)
132. Ando M, "Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 24, pp.2549~2556 (2006)
133. Cohen MH, "FDA drug approval summary : erlotinib(Tarceva)tablets", Oncologist, 10, pp.461~466 (2005)
134. Lopez JS, "Combine and conquer : challenges for targeted therapy combinations in early phase trials", Nat Rev Clin Oncol, 14, pp.57~66 (2017)
135. Desai A, "Trends in prices of drugs used to treat metastatic non-small cell lung cancer in the US from 2015 to 2020", JAMA Netw Open, 5, pp.e2144923~ (2022)
136. Shih YC, "Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly : 2001 to 2011", J Clin Oncol, 33, pp.2190~2196 (2015)
137. Shilpakar R, "Lung cancer in Nepal", J Thorac Oncol, 17, pp.22~29 (2022)

관련 논문AI추천